Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
9 pending office actions • 5 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Public University Corporation Yokohama City University is currently managing 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 10 distinct examiners, indicating that each pending matter is being reviewed by a different individual. The portfolio is active across 6 distinct art units, which suggests a diverse range of technical focuses within the broader biotechnology sector and requires coordination across multiple examination groups.
SALMON, KATHERINE D is identified as the busiest examiner for the university. This examiner is responsible for 1 pending office action. Because there are 10 distinct examiners for 10 pending actions, the workload is perfectly distributed, with no single examiner handling more than one case. This lack of consolidation means that the university must navigate 10 different examiner styles simultaneously.
Practitioners should note that the 6 distinct art units involve multiple examiners per unit in some instances, given there are 10 examiners in total. This concentration within specific art units may allow for some consistency in group-level policies, even as individual examiner styles vary. The 1 pending office action assigned to the busiest examiner confirms that no single examiner has a dominant role in the current prosecution pipeline.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (11%) |
| §103 only | 1 (11%) |
| §102 only | 1 (11%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 5 (56%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
| DIETZ, NOE ROBERT | 1 | 0.0% | +0.0% |
| TRAN, LARA LINH | 1 | 16.7% | +90.9% |
| LANDEEN, BROGAN RANE | 1 | 28.6% | -33.3% |
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
| MATTHEWS, CHRISTINE HOPKINS | 1 | 71.7% | +31.3% |
| DAUNER, JOSEPH G | 1 | 56.9% | +35.2% |
| MOLOYE, TITILAYO | 1 | 62.5% | +47.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799496 | NUCLEIC ACID CONSTRUCT, AND THERAPEUTIC OR DIAGNOSTIC AGENT FOR MISMATCH REPAIR DEFICIENT CANCERS COMPRISING NUCLEIC ACID CONSTRUCT | CASH, KAILEY ELIZABETH | 49d overdue |
| 17762908 | METHOD FOR INDUCING HEPATOCYTE PLASTICITY | ROGERS, ERIC JASON | 29d |
| 18684590 | NUCLEIC ACID CONSTRUCT CAPABLE OF MEASURING HOMOLOGOUS RECOMBINATION ACTIVITY AND UTILIZATION THEREOF | SALMON, KATHERINE D | — |
| 18611777 | CANCER TREATMENT APPARATUS | DIETZ, NOE ROBERT | — |
| 18607560 | CANCER TREATMENT APPARATUS AND METHOD OF CONTROLLING CANCER TREATMENT APPARATUS | TRAN, LARA LINH | — |
| 18347886 | POWER SUPPLY APPARATUS AND MAGNETIC FIELD GENERATION SYSTEM | LANDEEN, BROGAN RANE | — |
| 17837001 | CANCER TREATMENT APPARATUS | MATTHEWS, CHRISTINE HOPKINS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799496 | NUCLEIC ACID CONSTRUCT, AND THERAPEUTIC OR DIAGNOSTIC AGENT FOR MISMATCH REPAIR DEFICIENT CANCERS COMPRISING NUCLEIC ACID CONSTRUCT | CASH, KAILEY ELIZABETH | 49d overdue |
| 17762908 | METHOD FOR INDUCING HEPATOCYTE PLASTICITY | ROGERS, ERIC JASON | 29d |
| 16969523 | Cell Mass Fusion Method | MOLOYE, TITILAYO | 62d |
| 18684590 | NUCLEIC ACID CONSTRUCT CAPABLE OF MEASURING HOMOLOGOUS RECOMBINATION ACTIVITY AND UTILIZATION THEREOF | SALMON, KATHERINE D | — |
| 18607560 | CANCER TREATMENT APPARATUS AND METHOD OF CONTROLLING CANCER TREATMENT APPARATUS | TRAN, LARA LINH | — |
| 17837001 | CANCER TREATMENT APPARATUS | MATTHEWS, CHRISTINE HOPKINS | — |
| 17632519 | PROBE-INDUCED HETERODUPLEX MOBILITY ASSAY | DAUNER, JOSEPH G | — |
| Art Unit | Apps |
|---|---|
| 3791 | 2 |
| 1683 | 1 |
| 1638 | 1 |
| 1682 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684590 | NUCLEIC ACID CONSTRUCT CAPABLE OF MEASURING HOMOLOGOUS RECOMBINATION ACTIVITY AND UTILIZATION THEREOF | SALMON, KATHERINE D | — | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18611777 | CANCER TREATMENT APPARATUS | DIETZ, NOE ROBERT | — | §102§103§112 | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18607560 | CANCER TREATMENT APPARATUS AND METHOD OF CONTROLLING CANCER TREATMENT APPARATUS | TRAN, LARA LINH | — | §102§103 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18347886 | POWER SUPPLY APPARATUS AND MAGNETIC FIELD GENERATION SYSTEM | LANDEEN, BROGAN RANE | 3791 | §103§112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 17799496 | NUCLEIC ACID CONSTRUCT, AND THERAPEUTIC OR DIAGNOSTIC AGENT FOR MISMATCH REPAIR DEFICIENT CANCERS COMPRISING NUCLEIC ACID CONSTRUCT | CASH, KAILEY ELIZABETH | 1683 | §102§103§112DP | Final Rejection | 49d overdue | Pending | Dec 21, 2022 |
| 17762908 | METHOD FOR INDUCING HEPATOCYTE PLASTICITY | ROGERS, ERIC JASON | 1638 | §103§112 | Non-Final OA | 29d | Pending | Oct 07, 2022 |
| 17837001 | CANCER TREATMENT APPARATUS | MATTHEWS, CHRISTINE HOPKINS | 3791 | §102§103§112 | Non-Final OA | — | Pending | Jun 09, 2022 |
| 17632519 | PROBE-INDUCED HETERODUPLEX MOBILITY ASSAY | DAUNER, JOSEPH G | 1682 | §102 | Final Rejection | — | Pending | Feb 03, 2022 |
| 16969523 | Cell Mass Fusion Method | MOLOYE, TITILAYO | 1632 | §103 | Final Rejection | 62d | Pending | Aug 12, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial